DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`1
`
`·1· · · · · · UNITED STATES PATENT AND TRADEMARK OFFICE
`
`·2· · · · · · BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`·3· ·------------------------------------
`
`·4· ·MYLAN PHARMACEUTICALS, INC. AND
`· · ·DR. REDDY'S LABORATORIES, INC.
`·5
`· · · · · · · · · · · ·Petitioners,
`·6
`· · ·v.· · · · · · · · · · · · · · · · · ·Case IPR2018-00272
`·7· · · · · · · · · · · · · · · · · · · · Patent 9,393,208 B2
`· · ·HORIZON PHARMA USA, INC.
`·8· ·AND NUVO PHARMACEUTICALS (IRELAND)
`· · ·DESIGNATED ACTIVITY COMPANY,
`·9
`· · · · · · · · · · · ·Patent Owners.
`10
`· · ·------------------------------------
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17· · · · ·VIDEOTAPED DEPOSITION UPON ORAL EXAMINATION
`· · · · · · · · · · OF DAVID A. JOHNSON, M.D.
`18· · · · · · · TAKEN ON BEHALF OF THE PETITIONERS
`
`19· · · · · · · · · · · Norfolk, Virginia
`
`20· · · · · · · · · · · · May 3, 2019
`
`21
`
`22
`
`23
`
`24
`
`25
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.com
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 1
`
`
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`1
`
`·1· · · · · · UNITED STATES PATENT AND TRADEMARK OFFICE
`
`·2· · · · · · BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`·3· ·------------------------------------
`
`·4· ·MYLAN PHARMACEUTICALS, INC. AND
`· · ·DR. REDDY'S LABORATORIES, INC.
`·5
`· · · · · · · · · · · ·Petitioners,
`·6
`· · ·v.· · · · · · · · · · · · · · · · · ·Case IPR2018-00272
`·7· · · · · · · · · · · · · · · · · · · · Patent 9,393,208 B2
`· · ·HORIZON PHARMA USA, INC.
`·8· ·AND NUVO PHARMACEUTICALS (IRELAND)
`· · ·DESIGNATED ACTIVITY COMPANY,
`·9
`· · · · · · · · · · · ·Patent Owners.
`10
`· · ·------------------------------------
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17· · · · ·VIDEOTAPED DEPOSITION UPON ORAL EXAMINATION
`· · · · · · · · · · OF DAVID A. JOHNSON, M.D.
`18· · · · · · · TAKEN ON BEHALF OF THE PETITIONERS
`
`19· · · · · · · · · · · Norfolk, Virginia
`
`20· · · · · · · · · · · · May 3, 2019
`
`21
`
`22
`
`23
`
`24
`
`25
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.com
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 1
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`2
`
`·1· ·Appearances:
`
`·2· · · · · · PERKINS COIE, LLP
`· · · · · · · By: MARIA A. STUBBINGS, ESQUIRE
`·3· · · · · · · · 700 13th Street, NW
`· · · · · · · · · Suite 600
`·4· · · · · · · · Washington, DC 20005-3960
`· · · · · · · · · (202)654-1742
`·5· · · · · · · · MStubbings@perkinscoie.com
`· · · · · · · · · Counsel for the Petitioners
`·6
`· · · · · · · COOLEY, LLP
`·7· · · · · · By: ELLEN A. SCORDINO, ESQUIRE
`· · · · · · · · · 500 Boylston Street
`·8· · · · · · · · Boston, MA 02116
`· · · · · · · · · (617)937-2492
`·9· · · · · · · · escordino@cooley.com
`· · · · · · · · · Counsel for the Patent Owner
`10· · · · · · · · Horizon Pharma USA, Inc.
`
`11· · · · · · BAKER BOTTS, LLP
`· · · · · · · By: JEFFREY S. GRITTON, ESQUIRE
`12· · · · · · · · 98 San Jacinto Boulevard
`· · · · · · · · · Suite 1500
`13· · · · · · · · Austin, TX 78701-4078
`· · · · · · · · · (512)322-2624
`14· · · · · · · · jeff.gritton@bakerbotts.com
`· · · · · · · · · Counsel for the Patent Owner
`15· · · · · · · · Nuvo Pharmaceuticals (Ireland)
`· · · · · · · · · Designated Activity Company
`16
`
`17
`
`18· · · · · · · · Also present:· Josh Bridges, Videographer
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.com
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 2
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`3
`
`·1· · · · · · · · · · ·I N D E X
`
`·2· ·WITNESS· · · · · · · · · · ·EXAMINATION BY· · · ·PAGE
`
`·3· ·David A. Johnson, M.D.· · · Ms. Stubbings· · · · · 5
`
`·4
`
`·5
`
`·6
`
`·7
`
`·8· · · · · · · · · ·E X H I B I T S
`
`·9· ·NO.· · · · · · · ·DESCRIPTION· · · · · · · · · · PAGE
`
`10· ·Exhibit 1· · · · ·Declaration of Dr. Johnson· · · 68
`
`11· ·Exhibit 1064· · · PDR 2000 excerpt· · · · · · · · 77
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 3
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`4
`
`·1· · · · · · · · Videotaped deposition upon oral
`
`·2· ·examination of DAVID A. JOHNSON, M.D., taken on behalf
`
`·3· ·of the Petitioners, before Penny C. Wile, RPR, RMR, CRR,
`
`·4· ·a Notary Public for the Commonwealth of Virginia at
`
`·5· ·large, taken pursuant to notice, commencing at 9:16 a.m.
`
`·6· ·on May 3, 2019, at the Norfolk Marriott Waterside, 235
`
`·7· ·East Main Street, Norfolk, Virginia, 23510.
`
`·8· · · · · · · · · · ·-· · -· · -
`
`·9· · · · · · · · THE VIDEOGRAPHER:· This is tape number one
`
`10· ·to the videotaped deposition of David A. Johnson, M.D.
`
`11· ·in the matter of Mylan Pharmaceuticals, Incorporated
`
`12· ·versus Horizon Pharma USA, being heard before the U.S.
`
`13· ·Patent and Trademark Office, File No. IPR2018-00272.
`
`14· · · · · · · · This deposition is being held at 235 East
`
`15· ·Main Street, Norfolk, Virginia on 5/3/2019.· The time is
`
`16· ·currently 9:16 a.m.
`
`17· · · · · · · · My name is Josh Bridges, and I'm the
`
`18· ·videographer.· The court reporter is Penny Wile.
`
`19· · · · · · · · Counsel, will you please introduce
`
`20· ·yourselves for the record and affiliations, and the
`
`21· ·witness will be sworn?
`
`22· · · · · · · · MS. STUBBINGS:· Maria Stubbings from
`
`23· ·Perkins Coie, representing Mylan.
`
`24· · · · · · · · MS. SCORDINO:· Ellen Scordino from Cooley,
`
`25· ·LLP, representing Horizon and the witness.
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 4
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`5
`
`·1· · · · · · · · MR. GRITTON:· Jeff Gritton from Baker
`
`·2· ·Botts, LLP, representing Nuvo.
`
`·3· · · · · · · · THE VIDEOGRAPHER:· Thank you.
`
`·4· · · · · · · · Please swear the witness.
`
`·5· · · · · · · · THE WITNESS:· I didn't hear what you said.
`
`·6
`
`·7· · · · · · · · DAVID A. JOHNSON, M.D. was sworn and
`
`·8· ·deposed on behalf of the Petitioner as follows:
`
`·9· · · · · · · · · · ·EXAMINATION
`
`10· ·BY MS. STUBBINGS:
`
`11· · · · · Q.· · Good morning, Dr. Johnson.
`
`12· · · · · A.· · Good morning.
`
`13· · · · · Q.· · So I know you've done this a few times
`
`14· ·before, so I'm going to go over a few ground rules, but
`
`15· ·I don't think we need to really go over anything in
`
`16· ·great detail.
`
`17· · · · · · · · So just a few things.· If you don't
`
`18· ·understand any of my questions, please let me know.
`
`19· ·Feel free to ask me to clarify, and I'll make an attempt
`
`20· ·to do so.· If you don't let me know that you don't
`
`21· ·understand a question that I ask, I'm going to assume
`
`22· ·that you do understand it.· Is that okay?
`
`23· · · · · A.· · Yes.
`
`24· · · · · Q.· · If you need a break at any time, just let
`
`25· ·me know and we can take a break.· I'll try to take
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 5
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`6
`
`·1· ·breaks every hour or so.· But if you -- if you need one,
`
`·2· ·we can certainly take one.· I'll just have you answer
`
`·3· ·whatever question that is pending, and then we can take
`
`·4· ·a break.
`
`·5· · · · · · · · And, then, just make sure to speak clearly
`
`·6· ·for the court reporter, especially, you know, in giving
`
`·7· ·affirmative yes and no answers instead of uh-huh or
`
`·8· ·uh-uh.· And, then, try not to speak in front of each
`
`·9· ·other.
`
`10· · · · · · · · That's it.· I think we can get started.
`
`11· · · · · · · · So I'm going to mark an exhibit, your
`
`12· ·declaration.· Did you -- oh, we did not.· Okay.
`
`13· · · · · · · · (Off-the-record discussion)
`
`14· ·BY MS. STUBBINGS:
`
`15· · · · · Q.· · So this -- yeah.· This -- this has already
`
`16· ·been marked Exhibit -- Patent Owners Exhibit 2026 in the
`
`17· ·proceeding.
`
`18· · · · · · · · MS. STUBBINGS:· Copies for you.· Here you
`
`19· ·go.
`
`20· · · · · · · · MS. SCORDINO:· Thank you.
`
`21· ·BY MS. STUBBINGS:
`
`22· · · · · Q.· · One for you, Dr. Johnson.
`
`23· · · · · · · · Dr. Johnson, do you recognize this
`
`24· ·document?
`
`25· · · · · A.· · Just give me a second.· This is --
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 6
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`7
`
`·1· · · · · Q.· · Sure.· Yeah.· Feel free to review it.
`
`·2· · · · · A.· · I do.
`
`·3· · · · · Q.· · Is this your declaration in IPR2018-272 on
`
`·4· ·Patent No. 9,393,208?
`
`·5· · · · · A.· · Yes.
`
`·6· · · · · Q.· · And over the course of today if I refer to
`
`·7· ·Patent No. two-zero-eight or two-oh-eight, do you
`
`·8· ·understand that I'm referring to Patent No. 9,393,208?
`
`·9· · · · · A.· · I do.
`
`10· · · · · Q.· · Great.· Thanks.
`
`11· · · · · · · · Could you please turn to -- I'm going to
`
`12· ·use the page numbers in the right-hand corner of the
`
`13· ·document, not the ones in the middle.· So if you can
`
`14· ·turn to page 41 of 128.
`
`15· · · · · · · · Can you just confirm for me that is your
`
`16· ·signature on page 41?
`
`17· · · · · A.· · It is.
`
`18· · · · · Q.· · Great.
`
`19· · · · · · · · Can you please turn to paragraph 56 of
`
`20· ·your report?
`
`21· · · · · A.· · What -- what page?
`
`22· · · · · Q.· · Oh.· Let me see.
`
`23· · · · · · · · 26.
`
`24· · · · · A.· · I have it.
`
`25· · · · · Q.· · Okay.· So in paragraph 56 you represent
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 7
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`8
`
`·1· ·that you have reviewed and agree with expert declaration
`
`·2· ·of Dr. Taft submitted in this proceeding.
`
`·3· · · · · · · · Did you have any conversations with
`
`·4· ·Dr. Taft?
`
`·5· · · · · A.· · No.
`
`·6· · · · · Q.· · Okay.· So you didn't speak with him on the
`
`·7· ·phone or in-person?
`
`·8· · · · · A.· · No.
`
`·9· · · · · Q.· · Okay.· So for this paragraph you just read
`
`10· ·Dr. Taft's opinions?
`
`11· · · · · · · · MS. SCORDINO:· Objection.· Vague.
`
`12· · · · · · · · THE WITNESS:· I -- I reviewed it.
`
`13· ·BY MS. STUBBINGS:
`
`14· · · · · Q.· · Okay.· Thank you.
`
`15· · · · · · · · Can you please turn to paragraph 21?· I'll
`
`16· ·get you a page number.
`
`17· · · · · · · · Page number 8.· And feel free to read all
`
`18· ·of paragraph 21.
`
`19· · · · · A.· · I have it.
`
`20· · · · · Q.· · So on paragraph 21 I'm looking
`
`21· ·particularly at the sentence that spans over into page
`
`22· ·9.· So you say, Here, I understand that conception and
`
`23· ·actual reduction to practice was ach -- were achieved by
`
`24· ·June 25th, 2007.
`
`25· · · · · · · · What is the basis for that understanding?
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 8
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`9
`
`·1· · · · · A.· · It's outlined in discussion by my
`
`·2· ·conversation and information provided by the legal
`
`·3· ·principles relating to the opinions in my expert
`
`·4· ·declaration.
`
`·5· · · · · Q.· · Okay.· So is it accurate to say that you
`
`·6· ·believe the conception and re -- reduction to practice
`
`·7· ·was achieved by June 25th, 2007 because of the clinical
`
`·8· ·study disclosing the claimed invention of the '208
`
`·9· ·patent?
`
`10· · · · · · · · MS. SCORDINO:· Objection to form.
`
`11· · · · · · · · THE WITNESS:· I understand that the -- the
`
`12· ·patent's entitled to the earliest priority date by which
`
`13· ·the invention is disclosed therein and conceived of and
`
`14· ·reduced to practice.
`
`15· ·BY MS. STUBBINGS:
`
`16· · · · · Q.· · Do you have any other basis to opine that
`
`17· ·the '208 patent is entitled to a priority date of June
`
`18· ·25th, 2007, other than the clinical study you mentioned
`
`19· ·in paragraph 21 of your report?
`
`20· · · · · · · · MS. SCORDINO:· Objection to form.
`
`21· · · · · · · · THE WITNESS:· If you can point me to
`
`22· ·someplace where I declare that in my declaration, I'll
`
`23· ·be happy to review that again.
`
`24· ·BY MS. STUBBINGS:
`
`25· · · · · Q.· · Sure.
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 9
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`10
`
`·1· · · · · · · · I just wanted to -- I know in paragraph 21
`
`·2· ·you mentioned the clinical study.· And I just wanted to
`
`·3· ·understand whether that's the only -- the only facts
`
`·4· ·that you -- that you're relying on to opine that the
`
`·5· ·'208 patent is entitled to a priority date of June 25th,
`
`·6· ·2007.· Is that correct?
`
`·7· · · · · A.· · Well, I understand that the patent's
`
`·8· ·entitled to the earliest priority, as stated in my
`
`·9· ·declaration.
`
`10· · · · · Q.· · Okay.· I'm going to give you another
`
`11· ·exhibit.· This exhibit is marked Mylan Pharms, Inc.
`
`12· ·Exhibit 1001.
`
`13· · · · · · · · Dr. Johnson, do you recognize this
`
`14· ·exhibit?
`
`15· · · · · A.· · I do.
`
`16· · · · · Q.· · What is it?
`
`17· · · · · A.· · The '208 patent.
`
`18· · · · · Q.· · Okay.· And do you see -- if you look at
`
`19· ·the first column on the first page, so page 1 of the
`
`20· ·'208 patent, it's the line starting at number 60.· So
`
`21· ·there is a number 60 on the left-hand side, all the way
`
`22· ·on the left-hand side of the page in parentheses.
`
`23· · · · · A.· · I have it.
`
`24· · · · · Q.· · And the '208 patent represents that the
`
`25· ·provisional application to which it claims priority --
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 10
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`11
`
`·1· ·Provisional Application No. 61-095,584 was filed on
`
`·2· ·September 9th, 2008.· Is that right?
`
`·3· · · · · · · · MS. SCORDINO:· Objection.· Outside the
`
`·4· ·scope.· Calls for a legal conclusion.
`
`·5· · · · · · · · THE WITNESS:· Line 60 says, Provisional
`
`·6· ·Application No. 61/095,584 filed on September 9, 2008.
`
`·7· ·BY MS. STUBBINGS:
`
`·8· · · · · Q.· · So in paragraph 21 of your expert
`
`·9· ·declaration you are giving the opinion that the '208
`
`10· ·patent is entitled to a priority date earlier than
`
`11· ·September 9th, 2008, right?
`
`12· · · · · A.· · Well, I stated I understand that a patent
`
`13· ·is entitled to the earliest priority date to which
`
`14· ·it's -- the invention is disclosed therein or conceived
`
`15· ·and put into -- reduced to practice.
`
`16· · · · · Q.· · Okay.· And June 25th, 2007 is earlier than
`
`17· ·September 9th, 2008, right?
`
`18· · · · · A.· · I'm sorry?· I don't understand what your
`
`19· ·question is.
`
`20· · · · · Q.· · Sorry.
`
`21· · · · · · · · June 25th, 2007, the date mentioned in
`
`22· ·paragraph 21 of your expert declaration, is earlier than
`
`23· ·September 9th, 2008, the date listed on the face of the
`
`24· ·'208 patent; is that correct?
`
`25· · · · · · · · MS. SCORDINO:· Objection to form.
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 11
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`12
`
`·1· · · · · · · · THE WITNESS:· As a calendar reference, the
`
`·2· ·answer is June 25th is different than the -- the other
`
`·3· ·date that you just mentioned, by calendar.
`
`·4· ·BY MS. STUBBINGS:
`
`·5· · · · · Q.· · And your opinion that the '208 patent is
`
`·6· ·entitled to a priority date of June 25th, 2007 is based
`
`·7· ·on the clinical study -- completion date for the
`
`·8· ·clinical study disclosing the claimed invention of the
`
`·9· ·'208 patent, right?
`
`10· · · · · · · · MS. SCORDINO:· Objection to form.· Asked
`
`11· ·and answered.
`
`12· · · · · · · · THE WITNESS:· As I said in my declaration,
`
`13· ·I understand that the patent is entitled to the earliest
`
`14· ·priority date by the -- which the invention was
`
`15· ·disclosed therein, was conceived of and reduced to
`
`16· ·practice.
`
`17· ·BY MS. STUBBINGS:
`
`18· · · · · Q.· · Okay.· Was the '208 -- the invention
`
`19· ·claimed in the '208 patent diligently reduced to
`
`20· ·practice?
`
`21· · · · · · · · MS. SCORDINO:· Objection to form.· Outside
`
`22· ·the scope.
`
`23· · · · · · · · THE WITNESS:· If you can point me to a
`
`24· ·point in my declaration that I discussed it, I'd be
`
`25· ·happy to review that comment.
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 12
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`13
`
`·1· ·BY MS. STUBBINGS:
`
`·2· · · · · Q.· · Sure.
`
`·3· · · · · · · · And I'll just -- I mean, you are free to
`
`·4· ·check for yourself.· I did not see any discussion of
`
`·5· ·diligence in your report.· I just want to make sure I'm
`
`·6· ·not missing anything.· But feel free to refer to your
`
`·7· ·report.
`
`·8· · · · · · · · But is it correct that you did not offer
`
`·9· ·any opinions on whether the '208 patent was diligently
`
`10· ·reduced to practice?
`
`11· · · · · · · · MS. SCORDINO:· Objection to form.
`
`12· · · · · · · · THE WITNESS:· And, again, if you can point
`
`13· ·that to me in my declaration, I'd be happy to review
`
`14· ·that.
`
`15· ·BY MS. STUBBINGS:
`
`16· · · · · Q.· · All right.· Did you review any documents
`
`17· ·to come to your opinion that the conception and actual
`
`18· ·reduction to practice of the '208 patented invention
`
`19· ·were achieved by June 25th, 2007?
`
`20· · · · · A.· · The documents that I reviewed are in my
`
`21· ·declaration.· And I'd be happy to review that comment
`
`22· ·if -- if you can point me to where I say that in my
`
`23· ·declaration.
`
`24· · · · · Q.· · Sure.
`
`25· · · · · · · · You don't actually cite to any documents
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 13
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`14
`
`·1· ·in paragraph 21 of your report, right?
`
`·2· · · · · · · · MS. SCORDINO:· Objection to form.
`
`·3· · · · · · · · THE WITNESS:· 21 stands as it's stated.
`
`·4· ·BY MS. STUBBINGS:
`
`·5· · · · · Q.· · Okay.· So paragraph 21 does not cite to
`
`·6· ·any documents; is that right?
`
`·7· · · · · · · · MS. SCORDINO:· Objection to form.· Lacks
`
`·8· ·foundation.
`
`·9· · · · · · · · THE WITNESS:· Again, I -- my -- that's
`
`10· ·left to your interpretation.· My -- my comments are very
`
`11· ·clear in the -- in point number 21.
`
`12· ·BY MS. STUBBINGS:
`
`13· · · · · Q.· · Sure.
`
`14· · · · · · · · And I'm just asking you to confirm things
`
`15· ·in your report.· So I don't -- I don't want to give any
`
`16· ·testimony here today.· So I'm just trying to get you to
`
`17· ·confirm what -- what my reading of certain things are.
`
`18· · · · · · · · What clinical study are you referring to
`
`19· ·in paragraph 21 of your report?
`
`20· · · · · A.· · Point to me where you -- where I cited
`
`21· ·the -- the clinical study.
`
`22· · · · · Q.· · Sure.
`
`23· · · · · · · · The -- the last sentence of paragraph 21,
`
`24· ·that starts on page 8 and goes over to page 9, that
`
`25· ·says, Here, I understand that conception and actual
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 14
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`15
`
`·1· ·reduction to practice were achieved by June 25th, 2007
`
`·2· ·when the clinical study disclosed -- disclosing the
`
`·3· ·claimed invention of the '208 patent was completed.
`
`·4· · · · · · · · What clinical study are you referring to
`
`·5· ·there?
`
`·6· · · · · A.· · The study of the '208 patent.
`
`·7· · · · · Q.· · The two-zero-eight patent?
`
`·8· · · · · A.· · The -- the study aimed at disclosing the
`
`·9· ·invention of the 2008 patent.
`
`10· · · · · Q.· · Okay.· And what clinical study was that?
`
`11· · · · · · · · MS. SCORDINO:· Objection.· This isn't a
`
`12· ·memory test.· Do you want him to come up with a number?
`
`13· · · · · · · · MS. STUBBINGS:· We can move on.
`
`14· ·BY MS. STUBBINGS:
`
`15· · · · · Q.· · Can you turn to paragraph 57 of your
`
`16· ·report?
`
`17· · · · · A.· · What page is that?
`
`18· · · · · Q.· · Let me get it for you.
`
`19· · · · · · · · Page 26.
`
`20· · · · · · · · So in section B of your declaration, in
`
`21· ·paragraphs 57 through 62, you're giving the opinion that
`
`22· ·the '285 patent is not prior art to claims 1 through 7
`
`23· ·of the '208 patent, right?
`
`24· · · · · A.· · I'm stating what I understand from counsel
`
`25· ·as the reference.
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 15
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`16
`
`·1· · · · · Q.· · Okay.· And I don't want to know what
`
`·2· ·counsel told you, so please don't disclose any -- any
`
`·3· ·substantive discussions with counsel.
`
`·4· · · · · · · · But aside from your discussions with
`
`·5· ·counsel, do you have any independent understanding of
`
`·6· ·whether the '285 patent is prior art to the '208 patent?
`
`·7· · · · · · · · MS. SCORDINO:· Objection to form.
`
`·8· · · · · · · · THE WITNESS:· Well, I think it would be --
`
`·9· ·it would be irresponsible for me to formulate an opinion
`
`10· ·without understanding from counsel since this is a legal
`
`11· ·proceeding.
`
`12· ·BY MS. STUBBINGS:
`
`13· · · · · Q.· · Okay.· Can you describe what you did,
`
`14· ·aside from your discussions with counsel, to formulate
`
`15· ·your opinion that the '285 patent is not prior art to
`
`16· ·the '208 patent?
`
`17· · · · · A.· · Sure.· If you'd point to me in my
`
`18· ·declaration my preparation statements, I'd be happy to
`
`19· ·review that with you.
`
`20· · · · · Q.· · Sure.· I believe that's in paragraphs 57
`
`21· ·through 62 of the report where we are now.
`
`22· · · · · A.· · Well, the understanding as outlined in the
`
`23· ·declaration is -- is quite clear as far as the documents
`
`24· ·that were reviewed.
`
`25· · · · · Q.· · Okay.· Can you walk me through what you
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 16
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`17
`
`·1· ·did to come to that understanding?
`
`·2· · · · · A.· · To review the patents and having
`
`·3· ·discussion with -- with counsel and understanding.
`
`·4· · · · · Q.· · Okay.· In paragraph 61 you state, In my
`
`·5· ·opinion, the claimed subject matter at issue in the '208
`
`·6· ·patent is comparable to the underlying subject matter
`
`·7· ·asserted as prior art in the '285 patent.
`
`·8· · · · · · · · What do you mean by "comparable"?
`
`·9· · · · · A.· · That's the word that came to mind.· That's
`
`10· ·what, in my mind, solidifies the statement.
`
`11· · · · · Q.· · Do you mean that the '285 patent is
`
`12· ·similar to the '208 patent?
`
`13· · · · · A.· · What I said was comparable.
`
`14· · · · · Q.· · Okay.· Can you give any -- any more
`
`15· ·description of what you mean by comparable?
`
`16· · · · · A.· · That's the best description that I can
`
`17· ·provide right now.
`
`18· · · · · Q.· · Okay.· So what I'm trying to get at is
`
`19· ·when I think of the word comparable, me personally, it
`
`20· ·seems like it could have multiple definitions.· It could
`
`21· ·mean that two patents, for example, are similar or it
`
`22· ·can mean these two documents can just be compared
`
`23· ·irrespective of whether they're similar or not.
`
`24· · · · · · · · When you say that the '285 patent is
`
`25· ·comparable to the '208 patent, do you mean that they're
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 17
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`18
`
`·1· ·similar or do you simply mean that you're comparing
`
`·2· ·them?
`
`·3· · · · · A.· · Well, in due respect to your opinion, and
`
`·4· ·I respect that, in my opinion they're comparable.
`
`·5· · · · · Q.· · Which comparable do you mean?
`
`·6· · · · · · · · MS. SCORDINO:· Objection to form.
`
`·7· · · · · · · · THE WITNESS:· The word -- the word
`
`·8· ·comparable is -- is the best description that I can have
`
`·9· ·and formulate in the way I would -- I would look at
`
`10· ·this.
`
`11· ·BY MS. STUBBINGS:
`
`12· · · · · Q.· · Is it your opinion that the claims of the
`
`13· ·'285 patent are similar to the claims of the '208
`
`14· ·patent?
`
`15· · · · · A.· · I believe I used the word comparable.
`
`16· · · · · Q.· · Okay.· So are the claims of the '285
`
`17· ·patent comparable to the claims of the '208 patent?
`
`18· · · · · A.· · In my opinion, the claimed subject matter
`
`19· ·at issue in the '208 is comparable to the underlying
`
`20· ·subject matter asserted as prior art in the '285 patent.
`
`21· · · · · Q.· · Is the claimed subject matter at issue in
`
`22· ·the '208 patent comparable to the '907 patent?
`
`23· · · · · A.· · If you point me to where I discuss the
`
`24· ·'907 patent as far as my opinion, I'd be happy to review
`
`25· ·that with you.
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 18
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`19
`
`·1· · · · · Q.· · Are the '208 patent and the '285 patent
`
`·2· ·different in any way?
`
`·3· · · · · · · · MS. SCORDINO:· Objection to form.
`
`·4· · · · · · · · THE WITNESS:· I didn't hear the --
`
`·5· ·BY MS. STUBBINGS:
`
`·6· · · · · Q.· · Sorry.
`
`·7· · · · · · · · Are the '208 patent and the '285 patent
`
`·8· ·different in any way?
`
`·9· · · · · A.· · In my opinion, the claimed subject matter
`
`10· ·in the '208 is comparable to the underlying subject
`
`11· ·matter asserted in the prior art of the '285 patent.
`
`12· · · · · Q.· · Sure.
`
`13· · · · · · · · And so does that mean, on the flip side,
`
`14· ·your opinion is that you -- they are not different?
`
`15· · · · · A.· · You'd have to point to where I -- that is
`
`16· ·declared in my -- in my statements here.· I'd be happy
`
`17· ·to review that with you.
`
`18· · · · · Q.· · Sure.
`
`19· · · · · · · · I think the only -- the only paragraph
`
`20· ·that discusses the comparability of these two patents is
`
`21· ·in paragraph 61, so I'm just focusing on that.
`
`22· · · · · · · · But I want to know that since your opinion
`
`23· ·is that the two patents are comparable or the subject
`
`24· ·matter is comparable, does that mean you do not believe
`
`25· ·that the two patents are different?
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 19
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`20
`
`·1· · · · · · · · MS. SCORDINO:· Objection to form.
`
`·2· · · · · · · · THE WITNESS:· In my opinion, the claimed
`
`·3· ·subject matter at issue is the '208 patent is comparable
`
`·4· ·to the underlying subject matter asserted as prior art
`
`·5· ·in the '285 patent.
`
`·6· ·BY MS. STUBBINGS:
`
`·7· · · · · Q.· · Okay.· We can come back to that.
`
`·8· · · · · · · · Actually, one more question on that.· Why
`
`·9· ·did you include this statement in your declaration?
`
`10· · · · · A.· · Which statement?
`
`11· · · · · Q.· · That the claimed subject matter at issue
`
`12· ·in the '208 patent is comparable to the underlying
`
`13· ·subject matter asserted as prior art in the '285 patent.
`
`14· · · · · A.· · I'd have to go back and consider at the
`
`15· ·time why -- why -- why I did that.· It made sense at the
`
`16· ·time.
`
`17· · · · · Q.· · What do you mean by "it made sense at the
`
`18· ·time"?
`
`19· · · · · A.· · Well, in discussion with the understanding
`
`20· ·with counsel and the -- the review of the documents,
`
`21· ·that was my opinion.
`
`22· · · · · Q.· · I'm going to hand you another exhibit.
`
`23· ·Dr. Johnson, this exhibit is Mylan Pharms, Inc. Exhibit
`
`24· ·1005.· Here you go.
`
`25· · · · · · · · Dr. Johnson, do you recognize this
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 20
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`21
`
`·1· ·exhibit?
`
`·2· · · · · A.· · I do.
`
`·3· · · · · Q.· · What is it?
`
`·4· · · · · A.· · As abbreviated, the '285 patent.
`
`·5· · · · · Q.· · Sure.
`
`·6· · · · · · · · And so just for housekeeping, Mylan
`
`·7· ·Pharms, Inc. Exhibit 1005, the top right corner states
`
`·8· ·that it is Patent No. 8,557,285.· And if I refer to this
`
`·9· ·patent over the course of the day as the '285 patent,
`
`10· ·you understand that I'm referring to this document,
`
`11· ·right?
`
`12· · · · · A.· · Yes.
`
`13· · · · · Q.· · Okay.· Thanks.
`
`14· · · · · · · · And to confirm, this is the patent that
`
`15· ·you believe is not prior art to the '208 patent, right?
`
`16· · · · · A.· · This is the '285 patent that's subject to
`
`17· ·my -- my declaration.
`
`18· · · · · Q.· · Okay.· Did you offer your opinions in this
`
`19· ·inter partes review proceeding under the assumption that
`
`20· ·the '285 patent is not prior art to the '208 patent?
`
`21· · · · · · · · MS. SCORDINO:· Objection to form.
`
`22· · · · · · · · THE WITNESS:· I'm not sure I understand
`
`23· ·the question.
`
`24· ·BY MS. STUBBINGS:
`
`25· · · · · Q.· · So for the opinions you gave on whether
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 21
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`22
`
`·1· ·the '208 patent is valid, did you offer those opinions
`
`·2· ·with the assumption that the '285 patent is not prior
`
`·3· ·art to the '205 -- '208 patent?
`
`·4· · · · · · · · MS. SCORDINO:· Objection to form.
`
`·5· · · · · · · · THE WITNESS:· Well, my opinion, the '285
`
`·6· ·patent didn't qual -- does not qualify as prior art by
`
`·7· ·another for there is a common inventor with
`
`·8· ·Dr. Plachetka in the subject matter of the '285 patent
`
`·9· ·and the claimed subject matter asserting the claims of
`
`10· ·the '208 patent.
`
`11· ·BY MS. STUBBINGS:
`
`12· · · · · Q.· · Let's turn back to Exhibit 1005, the '285
`
`13· ·patent.· Would you please turn to page 10 of Exhibit
`
`14· ·1005?· And if you look at column 1, I am looking at the
`
`15· ·paragraph that starts on line, I think, 48 of the first
`
`16· ·column.
`
`17· · · · · A.· · 48 of the first column?
`
`18· · · · · Q.· · Yeah.· The paragraph starts, In general.
`
`19· ·Are you there?
`
`20· · · · · A.· · I have it.
`
`21· · · · · Q.· · Great.
`
`22· · · · · · · · So the '285 patent discloses that
`
`23· ·proton-pump inhibitors are thought to be more protective
`
`24· ·during chronic administration events than short --
`
`25· ·shorter acting agents such as H2-receptor antagonists;
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1085 PAGE 22
`
`
`
`DAVID A. JOHNSON M.D.
`DAVID A. JOHNSON M.D.
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`MYLAN PHARMACEUTICALS vs HORIZON PHARMA
`
`May 03, 2019
`May 03, 2019
`23
`
`·1· ·is that right?
`
`·2· · · · · A.· · In general.
`
`·3· · · · · Q.· · Okay.· And to support that statement the
`
`·4· ·'285 patent cites two articles from 1998, right?
`
`·5· · · · · A.· · Correct.
`
`·6· · · · · · · · MS. STUBBINGS:· And just for the court
`
`·7· ·reporter, when I say NSAIDs -- you've got that -- it's
`
`·8· ·N-S-A-I-D.
`
`·9· ·BY MS. STUBBINGS:
`
`10· · · · · Q.· · And if you look at -- Dr. Johnson, if you
`
`11· ·look at column 2 of page 10, I'm looking at the
`
`12· ·paragraph around line 26 that starts, Recognizing the
`
`13· ·potential benefits.
`
`14· · · · · A.· · I have it.
`
`15· · · · · Q.· · Great.
`
`16· · · · · · · · And feel free to review that paragraph.
`
`17· ·But do you agree that the '285 patent discloses that
`
`18· ·others in the art recognize the potential benefits of
`
`19· ·proton-pump inhibitors, or PPIs, for the prevention of
`
`20· ·NSAID-induced gastroduodenal damage and have disclosed
`
`21· ·strategies for combining PPIs and NSAIDs
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
